Casdin Capital Amends Standard BioTools Stake on Jan 5 Event

TL;DR

**Casdin Capital just updated its stake in Standard BioTools, watch for potential market reaction.**

AI Summary

Casdin Capital, LLC filed an amended Schedule 13D/A on January 9, 2024, indicating a change in their beneficial ownership of Standard BioTools Inc. common stock. The filing, triggered by an event on January 5, 2024, updates their previous disclosure regarding their stake in the company. This matters to investors because Casdin Capital is a significant institutional holder, and changes in their position can signal their evolving confidence in Standard BioTools' future prospects, potentially influencing other investors' decisions.

Why It Matters

Changes in major institutional investor holdings like Casdin Capital's can signal shifts in confidence, potentially impacting stock price and investor sentiment for Standard BioTools Inc.

Risk Assessment

Risk Level: medium — While not a direct sale or purchase, an amendment to a 13D filing can indicate a change in the investor's intentions or holdings, introducing uncertainty.

Analyst Insight

Investors should review the full SC 13D/A filing to understand the specific changes in Casdin Capital's beneficial ownership or intentions, as this amendment only signals a change occurred, not the details of that change. This could inform their own assessment of Standard BioTools Inc.

Key Players & Entities

• Casdin Capital, LLC (company) — the reporting person filing the SC 13D/A
• Standard BioTools Inc. (company) — the issuer of the securities
• Eli Casdin (person) — contact person for Casdin Capital, LLC
• $0.001 (dollar_amount) — par value per share of Common Stock
• January 5, 2024 (date) — date of the event requiring the filing

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $78,750,000 — F in exchange for cash consideration of $78,750,000 and (b) 33,750 shares of Series B-1 Pre
• $33,750,000 — I in exchange for cash consideration of $33,750,000. Pursuant to the Loan Agreement (define
• $8,750,000 — aggregate original principal amount of $8,750,000 and (ii) Casdin PGEII provided a term l
• $3,750,000 — aggregate original principal amount of $3,750,000. Upon the issuance of the Series B-1 Pr
• $0.0001 — of common stock of SomaLogic, par value $0.0001 per share ("SomaLogic Common Stock"), w
• $25,000,000 — to result in gross proceeds of at least $25,000,000, (b) if three underwritten offerings ha
• $1,000 — greater than 250% of an amount equal to $1,000 divided by the Conversion Rate as of su

Filing Documents

• d10932246_13d-a.htm (SC 13D/A) — 175KB
• 0000919574-24-000217.txt ( ) — 177KB

From the Filing

SC 13D/A 1 d10932246_13d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 (212) 897-5430 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 5, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d1(f) or 240.13d-1(g), check the following box [ ]. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. CUSIP No. 34385P108 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Casdin Capital, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] 3. SEC USE ONLY 4. SOURCE OF FUNDS AF 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 52,773,091 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 52,773,091 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 52,773,091 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 16.17% 14. TYPE OF REPORTING PERSON IA CUSIP No. 34385P108 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Casdin Private Growth Equity Fund II, L.P. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] 3. SEC USE ONLY 4. SOURCE OF FUNDS WC 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 11,274,704 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 11,274,704 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,274,704 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.45% 14. TYPE OF REPORTING PERSON PN CUSIP No. 34385P108 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Casdin Private Growth Equity Fund II GP, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] 3. SEC USE ONLY 4. SOURCE OF FUNDS AF 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 11,274,704 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 11,274,704 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,274,704 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.45% 14. TYPE OF REPORTING PERSON OO CUSIP No. 34385P108 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Casdin Partners Master Fund, L.P. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] 3. SEC USE ONLY 4. SOURCE OF FUNDS WC 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 6. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 37,554,168 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 37,554,168 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 37,554,168 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.51% 14. TYPE OF REPORTING PERSON PN CUSIP No. 34385P108 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Casdin Partners GP, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_]

View Full Filing

View this SC 13D/A filing on SEC EDGAR